Search

Your search keyword '"VOSS, F."' showing total 862 results
Start Over Author "VOSS, F."
862 results on '"VOSS, F."'

4. Effect of Cytomegalovirus Prophylaxis with Immunoglobulins or Antiviral Drugs on Lymphoproliferative Disease After Heart Transplantation: Single-Center Experience in 300 Patients

Author

Boeken, U., primary, Hettlich, V., additional, Jenkins, F., additional, Sigetti, D., additional, Böttger, C., additional, Scheiber, D., additional, Polzin, A., additional, Voss, F., additional, Dalyanoglu, H., additional, Ramadani, B., additional, Aubin, H., additional, and Lichtenberg, A., additional

Published
2024
Full Text
View/download PDF

5. Measurement and analysis of the Am-243 neutron capture cross section at the n_TOF facility at CERN

Author

Collaboration, n_TOF, Mendoza, E., Cano-Ott, D., Guerrero, C., Berthoumieux, E., Abbondanno, U., Aerts, G., Alvarez-Velarde, F., Andriamonje, S., Andrzejewski, J., Assimakopoulos, P., Audouin, L., Badurek, G., Balibrea, J., Baumann, P., Becvar, F., Belloni, F., Calvino, F., Calviani, M., Capote, R., Carrapico, C., de Albornoz, A. Carrillo, Cennini, P., Chepel, V., Chiaveri, E., Colonna, N., Cortes, G., Couture, A., Cox, J., Dahlfors, M., David, S., Dillmann, I., Dolfini, R., Domingo-Pardo, C., Dridi, W., Duran, I., Eleftheriadis, C., Ferrant, L., Ferrari, A., Ferreira-Marques, R., Fitzpatrick, L., Frais-Koelbl, H., Fujii, K., Furman, W., Goncalves, I., Gonzalez-Romero, E., Goverdovski, A., Gramegna, F., Griesmayer, E., Gunsing, F., Haas, B., Haight, R., Heil, M., Herrera-Martinez, A., Igashira, M., Isaev, S., Jericha, E., Kappeler, F., Kadi, Y., Karadimos, D., Karamanis, D., Ketlerov, V., Kerveno, M., Koehler, P., Konovalov, V., Kossionides, E., Krticka, M., Lampoudis, C., Leeb, H., Lindote, A., Lopes, I., Lossito, R., Lozano, M., Lukic, S., Marganiec, J., Marques, L., Marrone, S., Martinez, T., Massimi, C., Mastinu, P., Mengoni, A., Milazzo, P. M., Moreau, C., Mosconi, M., Neves, F., Oberhummer, H., Brien, S. O, Oshima, M., Pancin, J., Papachristodoulou, C., Papadopoulos, C., Paradela, C., Patronis, N., Pavlik, A., Pavlopoulos, P., Perrot, L., Pigni, M. T., Plag, R., Plompen, A., Plukis, A., Poch, A., Praena, J., Pretel, C., Quesada, J., Rauscher, T., Reifarth, R., Rosetti, M., Rubbia, C., Rudolf, G., Rullhusen, P., Salgado, J., Santos, C., Sarchiapone, L., Savvidis, I., Stephan, C., Tagliente, G., Tain, J. L., Tassan-Got, L., Tavora, L., Terlizzi, R., Vannini, G., Vaz, P., Ventura, A., Villamarin, D., Vicente, M. C., Vlachoudis, V., Vlastou, R., Voss, F., Walter, S., Wendler, H., Wiescher, M., and Wisshak, K.

Subjects
Nuclear Experiment
Abstract

Background:The design of new nuclear reactors and transmutation devices requires to reduce the present neutron cross section uncertainties of minor actinides. Purpose: Reduce the $^{243}$Am(n,$\gamma$) cross section uncertainty. Method: The $^{243}$Am(n,$\gamma$) cross section has been measured at the n_TOF facility at CERN with a BaF$_{2}$ Total Absorption Calorimeter, in the energy range between 0.7 eV and 2.5 keV. Results: The $^{243}$Am(n,$\gamma$) cross section has been successfully measured in the mentioned energy range. The resolved resonance region has been extended from 250 eV up to 400 eV. In the unresolved resonance region our results are compatible with one of the two incompatible capture data sets available below 2.5 keV. The data available in EXFOR and in the literature has been used to perform a simple analysis above 2.5 keV. Conclusions: The results of this measurement contribute to reduce the $^{243}$Am(n,$\gamma$) cross section uncertainty and suggest that this cross section is underestimated up to 25% in the neutron energy range between 50 eV and a few keV in the present evaluated data libraries.

Published
2014
Full Text
View/download PDF

7. Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer

Author

Voss, F, primary, Nienhaus, F, additional, Pietruchs, S, additional, Melz, T, additional, Cramer, M, additional, Haberkorn, S M, additional, Ruckhaeberle, E, additional, Fehm, T, additional, Floegel, U, additional, Westenfeld, W, additional, Scheiber, D, additional, Jung, C, additional, Kelm, M, additional, Polzin, A, additional, and Boenner, F, additional

Published
2023
Full Text
View/download PDF

8. Validating available Donor-recipient risk assessment tools in a German Heart Transplant cohort

Author

Oehler, D, primary, Boettger, C, additional, Sigetti, D, additional, Voss, F, additional, Haurand, J M, additional, Ballazs, C, additional, Hoeckmann, M, additional, Kalampokas, N, additional, Aubin, H, additional, Scheiber, D, additional, Horn, P, additional, Polzin, A, additional, Kelm, M, additional, Lichtenberg, A, additional, and Boeken, U, additional

Published
2023
Full Text
View/download PDF

11. Effects of baseline symptom burden on treatment response in COPD

Author

Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, and Singh D

Subjects
tiotropium, olodaterol, COPD, Diseases of the respiratory system, RC705-779
Abstract

Fernando J Martinez,1 Roger A Abrahams,2,3 Gary T Ferguson,4 Leif Bjermer,5 Lars Grönke,6 Florian Voß,7 Dave Singh8 1Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY, USA; 2Morgantown Pulmonary Clinical Research, Morgantown, WV, USA; 3Department of Pulmonary & Critical Care, Mon Health Care, Morgantown, WV, USA; 4Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 5Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 6Biotechnology, CSL Behring, Wiesbaden, Germany; 7Biostatistics + Data Sciences Corp., Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 8Medicines Evaluation Unit, University of Manchester, Manchester, UK Rationale: In symptomatic patients with COPD, the decision whether to initiate maintenance treatment with a single agent or a combination of long-acting bronchodilators remains unclear. Objective: To investigate whether baseline symptomatic status influences response to tiotropium/olodaterol treatment. Materials and methods: Post hoc analysis of the randomized OTEMTO® studies (NCT01964352; NCT02006732), in which patients with moderate-to-severe COPD received placebo, tiotropium 5 µg, tiotropium/olodaterol 2.5/5 µg, or tiotropium/olodaterol 5/5 µg once daily for 12 weeks via the Respimat® inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany). Impact of baseline symptomatic status (modified Medical Research Council [mMRC] score) on response to treatment with tiotropium/olodaterol 5/5 µg, tiotropium 5 µg, or placebo at Week 12 was assessed by St George’s Respiratory Questionnaire (SGRQ) total score and response rate, transition dyspnea index (TDI) focal score and response rate, and trough forced expiratory volume in 1 second response. Results: Tiotropium/olodaterol improved SGRQ total scores and response rates compared with placebo and tiotropium for patients with baseline mMRC scores 0–1 and ≥2. For tiotropium/olodaterol vs tiotropium, greater improvements were observed for patients with mMRC ≥2 (SGRQ score adjusted mean treatment difference -3.44 [95% CI: -5.43, -1.46]; P=0.0007; SGRQ response rate ORs 2.09 [95% CI: 1.41, 3.10]; P=0.0002). Dyspnea, measured by TDI score, was consistently improved with tiotropium/olodaterol vs placebo for patients with mMRC scores 0–1 and ≥2 (adjusted mean treatment difference 1.63 [95% CI: 1.06, 2.20]; P

Published
2019

12. 128Xe and 130Xe: Testing He-shell burning in AGB stars

Author

Reifarth, R., Kaeppeler, F., Voss, F., Wisshak, K., Gallino, R., Pignatari, M., and Straniero, O.

Subjects
Astrophysics
Abstract

The s-process branching at 128I has been investigated on the basis of new, precise experimental (n,g) cross sections for the s-only isotopes 128Xe and 130Xe. This branching is unique, since it is essentially determined by the temperature- and density-sensitive stellar decay rates of 128I and only marginally affected by the specific stellar neutron flux. For this reason it represents an important test for He-shell burning in AGB stars. The description of the branching by means of the complex stellar scenario reveals a significant sensitivity to the time scales for convection during He shell flashes, thus providing constraints for this phenomenon. The s-process ratio 128Xe/130Xe deduced from stellar models allows for a (9+-3)% p-process contribution to solar 128Xe, in agreement with the Xe-S component found in meteoritic presolar SiC grains., Comment: 24 pages, 9 figures, accepted for publication in Astophysical Journal

Published
2004
Full Text
View/download PDF

13. GEANT simulations of neutron capture experiments with a 4p BaF2 detector

Author

Heil, M., Reifarth, R., Kaeppeler, F., Wisshak, K., Voss, F., Ullmann, J. L., Haight, R. C., Seabury, E. H., Wilhelmy, J. B., Rundberg, R. S., and Fowler, M. M.

Subjects
Nuclear Experiment
Abstract

The goal of this research project is to give quantitative information useful for the design of a g-ray detector to investigate neutron capture (n, g) reactions on radioactive nuclei at the Manuel Lujan Jr. Neutron Scattering Center (MLNSC) moderated neutron source at LANSCE. Data for neutron energies from thermal up to approximately 500 keV are desired. The radioactive nuclei can have half-lives as short as a few months. With the sample sizes foreseen, typically 1 mg, the radioactive decay rate can exceed tens of Curies (Ci)., Comment: 50 pages, 41 figures, LANL report

Published
2004

14. De Novo Malignancies after Heart Transplantation—A Single Center Experience.

Author

Sigetti, D., Jenkins, F.S., Hettlich, V.H., Boettger, C.S., Dalyanoglu, H., Tokhi, U., Voß, F., Scheiber, D., Aubin, H., Lichtenberg, A., and Boeken, U.

Subjects
HEART transplantation, KIDNEY transplantation, HEART transplant recipients, SKIN cancer
Abstract

This article discusses the incidence and risk factors for malignancies in patients who have undergone heart transplantation at a single center. The study analyzed data from 296 patients who had undergone heart transplantation between September 2010 and August 2023. The overall incidence of malignancy was 8.8%, with skin cancer being the most common type. The study found that the switch to everolimus as part of the immunosuppression therapy did not reduce the incidence of malignancies. Early detection through close follow-up is important for improving the prognosis of these malignancies. [Extracted from the article]

Published
2024
Full Text
View/download PDF

15. POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE

Author

Maher, T., primary, Assassi, S., additional, Azuma, A., additional, Cottin, V., additional, Hoffmann-Vold, A. M., additional, Kreuter, M., additional, Oldham, J., additional, Richeldi, L., additional, Valenzuela, C., additional, Wijsenbeek, M., additional, Coeck, C., additional, Voss, F., additional, Wachtlin, D., additional, and Martinez, F., additional

Published
2023
Full Text
View/download PDF

21. Sécurité d’emploi et efficacité de Bl 1015550, un inhibiteur préférentiel de la phosphodiestérase 4B (PDE4Bi), chez des patients atteints de fibrose pulmonaire idiopathique : essai de phase II

Author

Richeldi, L., primary, Azuma, A., additional, Cottin, V., additional, Hesslinger, C., additional, Stowasser, S., additional, Valenzuela, C., additional, Wijsenbeek, M., additional, Zoz, D.F., additional, Voss, F., additional, and Maher, T.M., additional

Published
2023
Full Text
View/download PDF

23. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age

Author

Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, and Buhl R

Subjects
COPD, bronchodilators, age, Diseases of the respiratory system, RC705-779
Abstract

Gary T Ferguson,1 Jill P Karpel,2 Emmanuelle Clerisme-Beaty,3 Lars Grönke,4 Florian Voß,4 Roland Buhl5 1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, 2North Shore Medical Arts LLP, Great Neck, NY, 3Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, 5Pulmonary Department, Mainz University Hospital, Mainz, Germany Background: Increasing age is associated with poor prognosis in patients with COPD. Objective: This analysis from the replicate Phase III OTEMTO® and TONADO® studies examined the efficacy and safety of tiotropium, a long-acting anticholinergic, combined with olodaterol, a long-acting β2-agonist, compared to monotherapies and placebo in patients with COPD aged 40 years to

Published
2016

24. The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies

Author

Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, and Fukuchi Y

Subjects
COPD, bronchodilators, maintenance treatment, Diseases of the respiratory system, RC705-779
Abstract

Masakazu Ichinose,1 Hiroyuki Taniguchi,2 Ayako Takizawa,3 Lars Grönke,4 Lazaro Loaiza,4 Florian Voß,4 Yihua Zhao,5 Yoshinosuke Fukuchi61Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; 2Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan; 3Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan; 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA; 6Juntendo University School of Medicine, Tokyo, JapanBackground: The efficacy and safety of once-daily tiotropium + olodaterol (T+O) maintenance treatment was demonstrated in the large, multinational, replicate, randomized, Phase III, Tonad® 1 (NCT01431274) and 2 (NCT01431287) studies in patients with moderate to very severe COPD. However, there may be racial differences in the effects of T+O on lung function in patients with COPD.Methods: In this Tondao® subgroup analysis, we assessed efficacy and safety of T+O in Japanese participants.Results: Versus the overall population, the 413 Japanese patients randomized and treated were slightly older, with more men, lower body mass index, lower baseline St George’s Respiratory Questionnaire (SGRQ) scores, fewer current smokers, but with higher pack-year smoking history. A lower proportion of Japanese patients used inhaled corticosteroids, short-acting muscarinic antagonists, or short- or long-acting β-adrenergic agonists at baseline, but use of long-acting muscarinic antagonists was higher. At Week 24, mean improvements with T+O 5/5 µg in forced expiratory volume in 1 second area under the curve from 0–3 hours response were 151 mL versus olodaterol and 134 mL versus tiotropium 5 µg; mean improvements with T+O 2.5/5 µg were 87 mL versus olodaterol and 70 mL versus tiotropium 2.5 µg. Mean improvements with T+O 5/5 µg in trough forced expiratory volume in 1 second were 131 mL versus olodaterol and 108 mL versus tiotropium 5 µg; mean improvements with T+O 2.5/5 µg were 60 mL versus olodaterol and 47 mL versus tiotropium 2.5 µg. SGRQ scores improved from baseline to a greater extent with both doses of T+O versus monotherapies. Responses were similar in the overall population. Adverse-event incidence was generally balanced across treatment groups.Conclusion: Consistent with results from the overall population, T+O 5/5 µg was superior to each monotherapy for lung function and SGRQ in the Japanese sub-population of patients with COPD in Tonado®.Keywords: COPD, bronchodilators, maintenance treatment

Published
2016

25. 10-year follow-up of interventional electrophysiology: updated German survey during the COVID-19 pandemic.

Author

Eckardt, Lars, Doldi, Florian, Busch, Sonia, Duncker, David, Estner, H., Kuniss, M., Metzner, A., Meyer, C., Neuberger, H.-R., Tilz, R., Voss, F., Steven, D., and Sommer, P.

Abstract

Introduction: This study provides an update of survey-based data providing an overview of interventional electrophysiology over the last decade. Overall infrastructure, procedures, and training opportunities in Germany were assessed. Methods: By analyzing mandatory quality reports, German cardiology centres performing electrophysiological studies were identified to repeat a questionnaire from 2010 and 2015. Results: A complete questionnaire was returned by 192 centers performing about 75% of all ablations in Germany in 2020. In the presence of the COVID-19 pandemic, a total of 76.304 procedures including 68.407 ablations were reported representing a 38% increase compared to 2015. The median number of ablations increased from 180 in 2010 to 377 in 2020. AF was the most common arrhythmia ablated (51 vs. 35% in 2010). PVI with radiofrequency point-by-point ablation (64%) and cryo-balloon ablation (34%) were the preferred strategies. Less than 50 (75) PVI were performed by 31% (36%) of all centres. Only 25 and 24% of participating centres fulfilled EHRA and national requirements for training centre accreditation, respectively. There was a high number of EP centres with no fellows (38%). The proportion of female fellows in EP increased from 26% in 2010 to 33% in 2020. Conclusion: Comparing 2020, 2010 and 2015, an increasing number of EP centres and procedures were registered. In 2020, more than every second ablation was for therapy of AF. In the presence of an increasing number of procedures, training opportunities were still limited, and most centres did not fulfill recommended EHRA or national requirements for accreditation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Author

Richeldi, L, Azuma, A, Cottin, V, Hesslinger, C, Stowasser, S, Valenzuela, C, Wijsenbeek, MS, Zoz, DF, Voss, F, Maher, TM, 1305-0013 Trial Investigators, Pulmonary Medicine, British Lung Foundation, National Institute for Health Research, Action for Pulmonary Fibrosis, CCA - Cancer Treatment and quality of life, and Pulmonary medicine

Subjects
Science & Technology, 1305-0013 Trial Investigators, PIRFENIDONE, General Medicine, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO, STANDARDIZATION, EFFICACY, NINTEDANIB, hosphodiesterase 4 (PDE4) inhibition, Medicine, General & Internal, SDG 3 - Good Health and Well-being, General & Internal Medicine, Life Sciences & Biomedicine, 11 Medical and Health Sciences
Abstract

BACKGROUND Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis. METHODS In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis. Patients were randomly assigned in a 2:1 ratio to receive BI 1015550 at a dose of 18 mg twice daily or placebo. The primary end point was the change from baseline in the forced vital capacity (FVC) at 12 weeks, which we analyzed with a Bayesian approach separately according to background nonuse or use of an antifibrotic agent. RESULTS A total of 147 patients were randomly assigned to receive BI 1015550 or placebo. Among patients without background antifibrotic use, the median change in the FVC was 5.7 ml (95% credible interval, -39.1 to 50.5) in the BI 1015550 group and -81.7 ml (95% credible interval, -133.5 to -44.8) in the placebo group (median difference, 88.4 ml; 95% credible interval, 29.5 to 154.2; probability that BI 1015550 was superior to placebo, 0.998). Among patients with background antifibrotic use, the median change in the FVC was 2.7 ml (95% credible interval, -32.8 to 38.2) in the BI 1015550 group and -59.2 ml (95% credible interval, -111.8 to -17.9) in the placebo group (median difference, 62.4 ml; 95% credible interval, 6.3 to 125.5; probability that BI 1015550 was superior to placebo, 0.986). A mixed model with repeated measures analysis provided results that were consistent with those of the Bayesian analysis. The most frequent adverse event was diarrhea. A total of 13 patients discontinued BI 1015550 treatment owing to adverse events. The percentages of patients with serious adverse events or severe adverse events were similar in the two trial groups. CONCLUSIONS In this placebo-controlled trial, treatment with BI 1015550, either alone or with background use of an antifibrotic agent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis. (Funded by Boehringer Ingelheim; 1305-0013 ClinicalTrials.gov number, NCT04419506.)

Published
2022

29. The use of local concentrated heat versus topical acyclovir for a herpes labialis outbreak: results of a pilot study under real life conditions

Author

Wohlrab J, Voß F, Müller C, and Brenn LC

Subjects
Dermatology, RL1-803
Abstract

Johannes Wohlrab,1 Franziska Voß,2 Christian Müller,2 Lars C Brenn21Department of Dermatology and Venereology, Martin Luther University of Halle-Wittenberg, Halle, 2Department of Medical Science and Operations, Riemser Pharma GmbH, Greifswald, GermanyBackground: Frequent outbreak of herpes labialis can affect quality of life by prodromes like burning, itching, and swelling. Topical applied preparations aim to shorten the duration of symptoms, inhibit the virus replication and/or accelerate the healing process. Local concentrated heat (LCH) can reduce burning, itching, or swelling of the skin by influence of mechano-heat sensitive afferent neurons.Patients and methods: To examine the effectiveness of two different topical applications (LCH versus topical acyclovir [TACV]) under real life conditions, we conducted a prospective, observational, reference-controlled cohort pilot study with 103 patients. Occurrence of prodromal burning, itching, swelling, and quality of life were assessed.Results: The LCH observation group (OG) showed a significantly faster improvement in all symptoms after 1-day of application than the TACV OG. The burden and duration of disease was lower and shorter in the LCH OG than in the TACV OG.Conclusions: The prodromal symptoms in recurrent herpes labialis were attenuated more effectively by LCH than by TACV.Keywords: herpes labialis, local concentrated heat, acyclovir

Published
2013

31. Procedure related complications following implantation of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) devices - Insights from the German DEVICE registry

Author

Kaiser, L, primary, Hochadel, M, additional, Senges, J, additional, Kleemann, T, additional, Szendey, I, additional, Voss, F, additional, Steinbeck, G, additional, Leschke, M, additional, Butter, C, additional, Becker, R, additional, Willems, S, additional, and Hakmi, S, additional

Published
2022
Full Text
View/download PDF

36. Towards a Sealed-Off Excimer Laser

Author

Voß, F., Bäumler, J., Rebhan, U., Basting, D., Waidelich, W., editor, Hügel, H., editor, Opower, H., editor, Tiziani, H., editor, Wallenstein, R., editor, and Zinth, W., editor

Published
1996
Full Text
View/download PDF

41. Neutron cross-sections for next generation reactors: New data from n_TOF

Author

Colonna, N., Abbondanno, U., Aerts, G., Álvarez, H., Álvarez-Velarde, F., Andriamonje, S., Andrzejewski, J., Assimakopoulos, P., Audouin, L., Badurek, G., Baumann, P., Becvar, F., Berthoumieux, E., Calviani, M., Calviño, F., Cano-Ott, D., Capote, R., Carrillo de Albornoz, A., Cennini, P., Chepel, V., Chiaveri, E., Cortes, G., Couture, A., Cox, J., Dahlfors, M., David, S., Dillman, I., Dolfini, R., Domingo-Pardo, C., Dridi, W., Duran, I., Eleftheriadis, C., Ferrant, L., Ferrari, A., Ferreira-Marques, R., Frais-Koelbl, H., Fujii, K., Furman, W., Goncalves, I., González-Romero, E., Goverdovski, A., Gramegna, F., Griesmayer, E., Guerrero, C., Gunsing, F., Haas, B., Haight, R., Heil, M., Herrera-Martinez, A., Igashira, M., Isaev, S., Jericha, E., Käppeler, F., Kadi, Y., Karadimos, D., Karamanis, D., Kerveno, M., Ketlerov, V., Koehler, P., Konovalov, V., Kossionides, E., Krticka, M., Lampoudis, C., Leeb, H., Lindote, A., Lopes, I., Lozano, M., Lukic, S., Marganiec, J., Marques, L., Marrone, S., Martínez, T., Massimi, C., Mastinu, P., Mengoni, A., Milazzo, P.M., Moreau, C., Mosconi, M., Neves, F., Oberhummer, H., O’Brien, S., Oshima, M., Pancin, J., Papachristodoulou, C., Papadopoulos, C., Paradela, C., Patronis, N., Pavlik, A., Pavlopoulos, P., Perrot, L., Pigni, M.T., Plag, R., Plompen, A., Plukis, A., Poch, A., Pretel, C., Quesada, J., Rauscher, T., Reifarth, R., Rosetti, M., Rubbia, C., Rudolf, G., Rullhusen, P., Salgado, J., Sarchiapone, L., Savvidis, I., Stephan, C., Tagliente, G., Tain, J.L., Tassan-Got, L., Tavora, L., Terlizzi, R., Vannini, G., Vaz, P., Ventura, A., Villamarin, D., Vicente, M.C., Vlachoudis, V., Vlastou, R., Voss, F., Walter, S., Wendler, H., Wiescher, M., and Wisshak, K.

Published
2010
Full Text
View/download PDF

43. Dissemination of data measured at the CERN n_TOF facility

Author

Dupont E., Otuka N., Cabellos O., Aberle O., Aerts G., Altstadt S., Alvarez H., Alvarez-Velarde F., Andriamonje S., Andrzejewski J., Audouin L., Bacak M., Badurek G., Balibrea J., Barbagallo M., Barros S., Baumann P., Bécares V., Bečvář F., Beinrucker C., Belloni F., Berthier B., Berthoumieux E., Billowes J., Boccone V., Bosnar D., Brown A., Brugger M., Caamaño M., Calviani M., Calviño F., Cano-Ott D., Capote R., Cardella R., Carrapiço C., Casanovas A., Castelluccio D.M., Cennini P., Cerutti F., Chen Y.H., Chiaveri E., Chin M., Colonna N., Cortés G., Cortés-Giraldo M.A., Cosentino L., Couture A., Cox J., Damone L.A., David S., Deo K., Diakaki M., Dillmann I., Domingo-Pardo C., Dressler R., Dridi W., Duran I., Eleftheriadis C., Embid-Segura M., Fernández-Domínguez B., Ferrant L., Ferrari A., Ferreira P., Finocchiaro P., Fraval K., Frost R.J.W., Fujii K., Furman W., Ganesan S., Garcia A.R., Gawlik A., Gheorghe I., Gilardoni S., Giubrone G., Glodariu T., Göbel K., Gomez-Hornillos M.B., Goncalves I.F., Gonzalez-Romero E., Goverdovski A., Gramegna F., Griesmayer E., Guerrero C., Gunsing F., Gurusamy P., Haight R., Harada H., Heftrich T., Heil M., Heinitz S., Hernández-Prieto A., Heyse J., Igashira M., Isaev S., Jenkins D.G., Jericha E., Kadi Y., Kaeppeler F., Kalamara A., Karadimos D., Karamanis D., Katabuchi T., Kavrigin P., Kerveno M., Ketlerov V., Khryachkov V., Kimura A., Kivel N., Kokkoris M., Konovalov V., Krtička M., Kroll J., Kurtulgil D., Lampoudis C., Langer C., Leal-Cidoncha E., Lederer C., Leeb H., Naour C. Le, Lerendegui-Marco J., Leong L.S., Licata M., Meo S. Lo, Lonsdale S.J., Losito R., Lozano M., Macina D., Manousos A., Marganiec J., Martinez T., Marrone S., Masi A., Massimi C., Mastinu P., Mastromarco M., Matteucci F., Maugeri E.A., Mazzone A., Mendoza E., Mengoni A., Milazzo P.M., Mingrone F., Mirea M., Mondelaers W., Montesano S., Moreau C., Mosconi M., Musumarra A., Negret A., Nolte R., O’Brien S., Oprea A., Palomo-Pinto F.R., Pancin J., Paradela C., Patronis N., Pavlik A., Pavlopoulos P., Perkowski J., Perrot L., Pigni M.T., Plag R., Plompen A., Plukis L., Poch A., Porras I., Praena J., Pretel C., Quesada J.M., Radeck D., Rajeev K., Rauscher T., Reifarth R., Riego A., Robles M., Roman F., Rout P.C., Rudolf G., Rubbia C., Rullhusen P., Ryan J.A., Sabaté-Gilarte M., Salgado J., Santos C., Sarchiapone L., Sarmento R., Saxena A., Schillebeeckx P., Schmidt S., Schumann D., Sedyshev P., Smith A.G., Sosnin N.V., Stamatopoulos A., Stephan C., Suryanarayana S.V., Tagliente G., Tain J.L., Tarifeño-Saldivia A., Tarrío D., Tassan-Got L., Tavora L., Terlizzi R., Tsinganis A., Valenta S., Vannini G., Variale V., Vaz P., Ventura A., Versaci R., Vermeulen M.J., Villamarin D., Vicente M.C., Vlachoudis V., Vlastou R., Voss F., Wallner A., Walter S., Ware T., Warren S., Weigand M., Weiß C., Wolf C., Wiesher M., Wisshak K., Woods P.J., Wright T., and Žugec P.

Subjects
Physics, QC1-999
Abstract

The n_TOF neutron time-of-flight facility at CERN is used for high quality nuclear data measurements from thermal energy up to hundreds of MeV. In line with the CERN open data policy, the n_TOF Collaboration takes actions to preserve its unique data, facilitate access to them in standardised format, and allow their re-use by a wide community in the fields of nuclear physics, nuclear astrophysics and various nuclear technologies. The present contribution briefly describes the n_TOF outcomes, as well as the status of dissemination and preservation of n_TOF final data in the international EXFOR library.

Published
2017
Full Text
View/download PDF

44. The n_TOF Total Absorption Calorimeter for neutron capture measurements at CERN

Author

Guerrero, C., Abbondanno, U., Aerts, G., Álvarez, H., Álvarez-Velarde, F., Andriamonje, S., Andrzejewski, J., Assimakopoulos, P., Audouin, L., Badurek, G., Baumann, P., Bečvář, F., Berthoumieux, E., Calviño, F., Calviani, M., Cano-Ott, D., Capote, R., Carrapiço, C., Cennini, P., Chepel, V., Chiaveri, E., Colonna, N., Cortes, G., Couture, A., Cox, J., Dahlfors, M., David, S., Dillmann, I., Domingo-Pardo, C., Dridi, W., Duran, I., Eleftheriadis, C., Ferrant, L., Ferrari, A., Ferreira-Marques, R., Fujii, K., Furman, W., Goncalves, I., González-Romero, E., Gramegna, F., Gunsing, F., Haas, B., Haight, R., Heil, M., Herrera-Martinez, A., Igashira, M., Jericha, E., Käppeler, F., Kadi, Y., Karadimos, D., Kerveno, M., Koehler, P., Kossionides, E., Krtička, M., Lampoudis, C., Leeb, H., Lindote, A., Lopes, I., Lozano, M., Lukic, S., Marganiec, J., Marrone, S., Martínez, T., Massimi, C., Mastinu, P., Mendoza, E., Mengoni, A., Milazzo, P.M., Moreau, C., Mosconi, M., Neves, F., Oberhummer, H., O’Brien, S., Pancin, J., Papachristodoulou, C., Papadopoulos, C., Paradela, C., Patronis, N., Pavlik, A., Pavlopoulos, P., Perrot, L., Pigni, M.T., Plag, R., Plompen, A., Plukis, A., Poch, A., Praena, J., Pretel, C., Quesada, J., Rauscher, T., Reifarth, R., Rubbia, C., Rudolf, G., Rullhusen, P., Salgado, J., Santos, C., Sarchiapone, L., Savvidis, I., Stephan, C., Tagliente, G., Tain, J.L., Tassan-Got, L., Tavora, L., Terlizzi, R., Vannini, G., Vaz, P., Ventura, A., Villamarin, D., Vicente, M.C., Vlachoudis, V., Vlastou, R., Voss, F., Walter, S., Wiescher, M., and Wisshak, K.

Published
2009
Full Text
View/download PDF

45. Measurement of the neutron-induced fission cross-section of 241Am at the time-of-flight facility n_TOF

Author

Belloni, F., Calviani, M., Colonna, N., Mastinu, P., Milazzo, P. M., Abbondanno, U., Aerts, G., Álvarez, H., Alvarez-Velarde, F., Andriamonje, S., Andrzejewski, J., Audouin, L., Badurek, G., Barbagallo, M., Baumann, P., Bečvář, F., Berthoumieux, E., Calviño, F., Cano-Ott, D., Capote, R., Carrapiço, C., Cennini, P., Chepel, V., Chiaveri, E., Cortes, G., Couture, A., Cox, J., Dahlfors, M., David, S., Dillmann, I., Domingo-Pardo, C., Dridi, W., Duran, I., Eleftheriadis, C., Embid-Segura, M., Ferrari, A., Ferreira-Marques, R., Fujii, K., Furman, W., Goncalves, I., Gonzalez-Romero, E., Goverdovski, A., Gramegna, F., Guerrero, C., Gunsing, F., Haas, B., Haight, R., Heil, M., Herrera-Martinez, A., Igashira, M., Jericha, E., Käppeler, F., Kadi, Y., Karadimos, D., Karamanis, D., Kerveno, M., Koehler, P., Kossionides, E., Krtička, M., Lamboudis, C., Leeb, H., Lindote, A., Lopes, I., Lozano, M., Lukic, S., Marganiec, J., Marrone, S., Martínez, T., Massimi, C., Meaze, M. H., Mengoni, A., Moreau, C., Mosconi, M., Neves, F., Oberhummer, H., O’Brien, S., Papachristodoulou, C., Papadopoulos, C., Paradela, C., Patronis, N., Pavlik, A., Pavlopoulos, P., Perrot, L., Pigni, M. T., Plag, R., Plompen, A., Plukis, A., Poch, A., Praena, J., Pretel, C., Quesada, J., Rauscher, T., Reifarth, R., Rosetti, M., Rubbia, C., Rudolf, G., Rullhusen, P., Salgado, J., Santos, C., Sarchiapone, L., Savvidis, I., Stephan, C., Tagliente, G., Tain, J. L., Tarrio, D., Tassan-Got, L., Tavora, L., Terlizzi, R., Vannini, G., Vaz, P., Ventura, A., Villamarin, D., Vincente, M. C., Vlachoudis, V., Vlastou, R., Voss, F., Walter, S., Wiescher, M., and Wisshak, K.

Published
2013
Full Text
View/download PDF

46. Measurement of the neutron-induced fission cross-section of 243Am relative to 235U from 0.5 to 20 MeV

Author

Belloni, F., Calviani, M., Colonna, N., Mastinu, P., Milazzo, P. M., Abbondanno, U., Aerts, G., Álvarez, H., Alvarez-Velarde, F., Andriamonje, S., Andrzejewski, J., Audouin, L., Badurek, G., Barbagallo, M., Baumann, P., Bečvář, F., Berthoumieux, E., Calviño, F., Cano-Ott, D., Capote, R., Carrapiço, C., Cennini, P., Chepel, V., Chiaveri, E., Cortes, G., Couture, A., Cox, J., Dahlfors, M., David, S., Dillmann, I., Domingo-Pardo, C., Dridi, W., Duran, I., Eleftheriadis, C., Embid-Segura, M., Ferrari, A., Ferreira-Marques, R., Fujii, K., Furman, W., Goncalves, I., Gonzalez-Romero, E., Goverdovski, A., Gramegna, F., Guerrero, C., Gunsing, F., Haas, B., Haight, R., Heil, M., Herrera-Martinez, A., Igashira, M., Jericha, E., Käppeler, F., Kadi, Y., Karadimos, D., Karamanis, D., Kerveno, M., Koehler, P., Kossionides, E., Krtička, M., Lamboudis, C., Leeb, H., Lindote, A., Lopes, I., Lozano, M., Lukic, S., Marganiec, J., Marrone, S., Martínez, T., Massimi, C., Meaze, M. H., Mengoni, A., Moreau, C., Mosconi, M., Neves, F., Oberhummer, H., O’Brien, S., Pancin, J., Papachristodoulou, C., Papadopoulos, C., Paradela, C., Patronis, N., Pavlik, A., Pavlopoulos, P., Perrot, L., Pigni, M. T., Plag, R., Plompen, A., Plukis, A., Poch, A., Praena, J., Pretel, C., Quesada, J., Rauscher, T., Reifarth, R., Rosetti, M., Rubbia, C., Rudolf, G., Rullhusen, P., Salgado, J., Santos, C., Sarchiapone, L., Savvidis, I., Stephan, C., Tagliente, G., Tain, J. L., Tarrio, D., Tassan-Got, L., Tavora, L., Terlizzi, R., Vannini, G., Vaz, P., Ventura, A., Villamarin, D., Vincente, M. C., Vlachoudis, V., Vlastou, R., Voss, F., Walter, S., Wiescher, M., and Wisshak, K.

Published
2011
Full Text
View/download PDF

47. Neutron-induced fission cross-section of 233U in the energy range 0.5 < En < 20 MeV

Author

Belloni, F., Calviani, M., Colonna, N., Mastinu, P., Milazzo, P. M., Abbondanno, U., Aerts, G., Álvarez, H., Alvarez-Velarde, F., Andriamonje, S., Andrzejewski, J., Audouin, L., Badurek, G., Baumann, P., Bečvář, F., Berthoumieux, E., Calviño, F., Cano-Ott, D., Capote, R., Carrapiço, C., Cennini, P., Chepel, V., Chiaveri, E., Cortes, G., Couture, A., Cox, J., Dahlfors, M., David, S., Dillmann, I., Domingo-Pardo, C., Dridi, W., Duran, I., Eleftheriadis, C., Embid-Segura, M., Ferrari, A., Ferreira-Marques, R., Fujii, K., Furman, W., Goncalves, I., Gonzalez-Romero, E., Goverdovski, A., Gramegna, F., Guerrero, C., Gunsing, F., Haas, B., Haight, R., Heil, M., Herrera-Martinez, A., Igashira, M., Jericha, E., Käppeler, F., Kadi, Y., Karadimos, D., Karamanis, D., Kerveno, M., Koehler, P., Kossionides, E., Krtička, M., Lamboudis, C., Leeb, H., Lindote, A., Lopes, I., Lozano, M., Lukic, S., Marganiec, J., Marrone, S., Martınez, T., Massimi, C., Meaze, M. H., Mengoni, A., Moreau, C., Mosconi, M., Neves, F., Oberhummer, H., O’Brien, S., Pancin, J., Papachristodoulou, C., Papadopoulos, C., Paradela, C., Patronis, N., Pavlik, A., Pavlopoulos, P., Perrot, L., Pigni, M. T., Plag, R., Plompen, A., Plukis, A., Poch, A., Praena, J., Pretel, C., Quesada, J., Rauscher, T., Reifarth, R., Rosetti, M., Rubbia, C., Rudolf, G., Rullhusen, P., Salgado, J., Santos, C., Sarchiapone, L., Savvidis, I., Stephan, C., Tagliente, G., Tain, J. L., Tassan-Got, L., Tavora, L., Terlizzi, R., Vannini, G., Vaz, P., Ventura, A., Villamarin, D., Vincente, M. C., Vlachoudis, V., Vlastou, R., Voss, F., Walter, S., Wiescher, M., Wisshak, K., and The n_TOF Collaboration

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results